GlaxoSmithKline (GSK) recently announced that their blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.

GSK said Blenrep did not meet the primary endpoint of “progression-free survival” – or the period of time that a person lives with the disease without it getting worse after treatment – in patients with relapsed or refractory multiple myeloma.

Read the full article here.